It is a pharma public limited company based in Nashik, Maharashtra, India, established in 1983.
1983 | Nashik, Maharashtra, India | ActiveNoble Drugs Limited, a active public limited company, was established on 21 March 1983 in Nashik, Maharashtra, India. Engaging in drug formulation & development within the pharma sector, it holds CIN: U24100MH1983PLC029592. Registered under ROC Roc Mumbai. it is unlisted. It has an authorized capital of ₹1.00 Cr and a paid-up capital of ₹9.91 M.
Formerly known as Noble Drugs P Limited. It upholds a compliant status. Its leadership includes Shriram Jagannath Dhamne (Director), Vilas Bharat Dhamne (Director), Dnyaneshwar Jagannath Dhamne (Managing Director). It holds no open charges and ₹1.73 Cr settled loans. Its latest AGM occurred on 30 September 2024, with the balance sheet filed on 31 March 2024. It is based at Flat No.4, Ashirwad Apartment Sharanpur Road, Nashik, Maharashtra, 422002.
U24100MH1983PLC029592
029592
21 March 1983
₹1.00 Cr
₹9.91 M
Roc Mumbai
Unlisted
Active
Explore comprehensive insights into Noble Drugs Limited — covering financial performance, compliance records, Competitor, shareholding patterns, directors, key metrics, and litigation history. Unlock to see detailed insights and stay informed.
Access Report
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Shriram Jagannath Dhamne | Director | 29 Jun 1995 | Current |
| Vilas Bharat Dhamne | Director | 01 Mar 1996 | Current |
| Dnyaneshwar Jagannath Dhamne | Managing Director | 20 Nov 1983 | Current |
Discover detailed profiles of directors and KMP - Unlock leadership insights today!
Noble Drugs Limited, for the financial year ended 2018, experienced significant growth in revenue, with a 47802.33% increase. The company also saw a substantial fall in profitability, with a 1657.1% decrease in profit. The company's net worth witnessed no change by increase of 0%.
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth | |||||||
| EBITDA |
|
In 2018, Noble Drugs had a promoter holding of 66.70% and a public holding of 33.30%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Reveal ownership structures and financial performance - Get instant access now!
₹0
₹17,349,000.00
| Date | Lender | Amount | Status |
|---|---|---|---|
| 06 Mar 2004 | Bank Of India | ₹0.67 M | Satisfied |
| 23 Jul 2002 | Bank Of India | ₹1.70 M | Satisfied |
| 18 Jun 2002 | Bank Of India | ₹0.50 M | Satisfied |
| 18 Jun 2002 | Bamk Of Indai | ₹0.50 M | Satisfied |
| 18 Jun 2002 | Bank Of India | ₹2.37 M | Satisfied |
Explore comprehensive loan charge details -
Unlock and access historical data on people associated with Noble Drugs, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Gain comprehensive insights into the Deals and Valuation data of Noble Drugs, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Noble Drugs's trajectory.
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
The activity Noble Drugs Limited last Annual general meeting of members was held on 30 Sep 2024 as per latest MCA records. was completed.
Progress on Noble Drugs Limited has filed its annual Financial statements for the year ended 31 Mar 2024 with Roc Mumbai. was documented.
Progress on A charge registered on 17 Jun 1986 via Charge ID 90215074 with Maha Rashtra State Financeal Corporation was fully satisfied on 01 Mar 2012. was documented.
Progress on A charge registered on 06 Mar 2004 via Charge ID 90211124 with Bank Of India was fully satisfied on 14 Nov 2011. was documented.
The activity A charge registered on 23 Jul 2002 via Charge ID 90213873 with Bank Of India was fully satisfied on 14 Nov 2011. was completed.
The activity A charge registered on 18 Jun 2002 via Charge ID 90215761 with Bamk Of Indai was fully satisfied on 14 Nov 2011. was completed.
The CIN of Noble Drugs Limited is U24100MH1983PLC029592.
Noble Drugs Limited is headquartered at Flat No.4, Ashirwad Apartment Sharanpur Road, Nashik, Maharashtra, 422002.
Noble Drugs Limited was incorporated on 21 March 1983.
The current directors of Noble Drugs Limited are
The primary industry of Noble Drugs Limited is Pharma.
Noble Drugs Limited is unlisted.
The authorized capital of Noble Drugs Limited is ₹1.00 Cr, and the paid-up capital is ₹9.91 M.
The compliance status of Noble Drugs Limited is Compliant.
Search company & director profiles for free and gain access to critical business data.
Company Details
+91-XXXXXXXXXX